Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination with Vopratelimab, an ICOS Agonist, in Biomarker-selected Subjects with Metastatic NSCLC After One Prior Platinum-containing Regimen II

Next Previous
Trial Profile

Phase 2 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination with Vopratelimab, an ICOS Agonist, in Biomarker-selected Subjects with Metastatic NSCLC After One Prior Platinum-containing Regimen II

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimivalimab (Primary) ; Vopratelimab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Concentra Biosciences; Jounce Therapeutics

Most Recent Events

  • 05 Dec 2023 This trial has been completed in Bulgaria, according to the European Clinical Trials Database record.
  • 17 Nov 2023 This trial has been completed in Slovakia, according to European Clinical Trials Database record.
  • 04 May 2023 According to a Jounce Therapeutics media release, Concentra Biosciences has completely acquired Jounce Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top